FeesSafety
Pluang+
Home/Explore/US Market Price/Stocks/NVO
icon
Us company
Asset icon - trade crypto, stocks, and gold on Pluang

Novo Nordisk A/S (NVO) Stock Price Today

TechnicalsFundamentalsFinancialsNewsCorp ActionAboutCompare
24H
1W
1M
3M
YTD
1Y
5Y

Aura AI Summary

Novo Nordisk (NVO) trades at $40.19, down 0.64% on the day, with strong technical support at $40 and resistance at $41. The company demonstrates robust fundamentals with Q1-Q3 2026 earnings beats, $309.1B revenue in 2025, and exceptional profitability metrics including 37.2% net income margin and 71.4% ROE. Recent developments include promising Wegovy pill data and strategic licensing deals worth nearly $4B to bolster its obesity drug pipeline.
NVO presents a compelling investment case with analyst consensus price target of $42.33 (5.3% upside) and 59% buy ratings. Key opportunities include leadership in GLP-1 obesity treatments and strong cash flow generation. Risks include FDA regulatory delays for hemophilia drug denecimig and intensifying competition from Eli Lilly in the weight-loss market. The stock's current valuation at 11.05 P/E appears reasonable given growth prospects.
Read full analysis

Key Stats

  • Market Cap
    $188.55B
  • Volume
    25,569,865
  • Sector
    Health
  • 52W High
    $63.98
  • 52W Low
    $35.29
  • Typical Hold Time
    118 Days
  • Enterprise Value
    $201.76B
  • Div Yield
    4.26%
  • Trading Activity
    56% Sell | 44% Buy
$40.57
52W Low: $35.29
30 Mar 2026
52W High: $63.98
26 Jan 2026

Track Novo Nordisk A/S (NVO) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Novo Nordisk A/S has traded between a low of $35.29 and a high of $63.98, highlighting its annual price range. Buy and sell Novo Nordisk A/S shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.

About Novo Nordisk A/S

With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Most Recent News

Content is generated by Aura AI

Hyperscalers invest hundreds of billions to boost AI data center accelerators amid rising demand.

Global tech giants like Amazon, Google, and Microsoft are committing hundreds of billions of dollars to expand AI-focused data center accelerators, driven by surging demand from generative AI workloads that exceed traditional CPU capabilities. These ...

Market News
43 minutes ago
Bcc Research
Bullish
news icon
Hyperscalers invest hundreds of billions to boost AI data center accelerators amid rising demand.

Dune completes SOC 2 Type II, boosting trust as tokenized assets hit $32.6B amid growing institutional blockchain use.

Dune has completed a SOC 2 Type II examination with no exceptions, providing institutional clients with verified assurance of its data security standards. This milestone comes as tokenized real-world assets doubled to $32.6 billion and stablecoin mar...

Market News
2 hours ago
Not Specified
Bullish
news icon
Dune completes SOC 2 Type II, boosting trust as tokenized assets hit $32.6B amid growing institutional blockchain use.

Opus Genetics completes dosing in Phase 1/2 trial for gene therapy targeting inherited retinal diseases

Opus Genetics has finished dosing the higher-dose Cohort 2 in its Phase 1/2 trial of OPGx-BEST1, a gene therapy for BEST1-related inherited retinal diseases like Best vitelliform macular dystrophy and autosomal recessive bestrophinopathy. Cohort 2 en...

Market News
3 hours ago
Na
Bullish
news icon
Opus Genetics completes dosing in Phase 1/2 trial for gene therapy targeting inherited retinal diseases
Catch up fast with Aura AI
Get an AI-generated news summary for this asset in seconds.

People also bought

Frequently Asked Questions

US stocks trading hours: Monday - Friday (Except for US public holidays) Time: 21.30 - 04.00 WIB 20.30 - 03.00 WIB (Daylight Savings Time*) *The next Daylight Savings is scheduled to begin on March 13, 2022 and ends on November 6, 2022. You can place limit orders outside of the trading hours, but it can only be executed during trading hours. For illustration, a stock is currently trading at $10 per share, but you only want to pay $7 per share at most. Let’s say you set your limit price to $7 at 18.00. Your order will be executed when the market is open at 21.30 if the stock drops from $10 to $7 or lower. Similarly, if the stock price doesn’t drop to $7, your order won’t be executed.
Yes, you are eligible to receive dividend payment if and when the company pays them on one condition: minimum net dividend paid is at least $0.01. Net dividend is gross dividend subtracted by 15% withholding tax.
Yes, it is. US Stocks risk is managed by PT PG Berjangka which is licensed by Badan Pengawas Perdagangan Berjangka Komoditi (BAPPEBTI), and your investment is guaranteed by Jakarta Futures Exchange (JFX) and Indonesian Clearing House (KBI).
Pluang charges a fixed transaction fee of 0.30% for regular users and 0.20% for Pluang Plus members, including VAT to cover the exchange fees and operational costs.
US Stocks, ETFs, and Options are facilitated by PT PG Berjangka in its capacity as a Licensed Derivatives Broker supervised by the Financial Services Authority of Indonesia (OJK) for financial derivative products with underlying securities. All transactions are recorded on the Jakarta Futures Exchange (JFX) and the Indonesian Futures Clearing House (KBI). In addition, PT PG Berjangka is also a Licensed Futures Broker supervised by the Commodity Futures Trading Regulatory Agency (Bappebti). Read our product’s Terms and Conditions

All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.

Key Stats

  • Market Cap
    $188.55B
  • Volume
    25,569,865
  • Sector
    Health
  • 52W High
    $63.98
  • 52W Low
    $35.29
  • Typical Hold Time
    118 Days
  • Enterprise Value
    $201.76B
  • Div Yield
    4.26%
  • Trading Activity
    56% Sell | 44% Buy
$40.57
52W Low: $35.29
30 Mar 2026
52W High: $63.98
26 Jan 2026

Track Novo Nordisk A/S (NVO) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Novo Nordisk A/S has traded between a low of $35.29 and a high of $63.98, highlighting its annual price range. Buy and sell Novo Nordisk A/S shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.

Let’s invest in this asset by signing up or download!